In this regard, the identification of a TM6SF2 variant linked to NAFLD susceptibility, its crucial involvement in very low-density lipoprotein (VLDL) lipidation, and its association as a risk factor for cardiovascular disease provide compelling evidence for the key role of TM6SF2 in the pathogenesis of NAFLD [5, 6]. This evidence concerns the gene TM6SF2 and metabolic dysfunction-associated steatotic liver disease.